American Journal of Cardiology
Volume 104, Issue 5 , Pages 638-643 , 1 September 2009

Usefulness of Elevations in Serum Choline and Free F2-Isoprostane to Predict 30-Day Cardiovascular Outcomes in Patients With Acute Coronary Syndrome

  • Rebecca M. LeLeiko, MD

      Affiliations

    • Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia
    • Corresponding Author InformationCorresponding author: Tel: (617) 638-8760; fax: (617) 638-8712
    • ,
  • Christopher S. Vaccari, MD

      Affiliations

    • Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Srikanth Sola, MD

      Affiliations

    • Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Nadya Merchant, PhD

      Affiliations

    • Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Sameer H. Nagamia, MD

      Affiliations

    • Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Martin Thoenes, MD

      Affiliations

    • Institute for Clinical Pharmacology, Technical University Dresden Medical Faculty Carl Gustav Carus, Dresden, Germany
    • Sanofi Aventis, Global Medical Affairs, Paris, France
    • ,
  • Bobby V. Khan, MD, PhD

      Affiliations

    • Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia

Received 23 February 2009 ,Revised 26 April 2009 ,Accepted 26 April 2009.

References 

  1. Möckel M, Danne O, Muller R, Vollert JO, Muller C, Lueders C, et al. Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. Clin Chim Acta. 2008;393:103–109
  2. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005;51:810–824
  3. Danne O, Lueders C, Storm C, Frei U, Möckel M. Whole blood choline and plasma choline in acute coronary syndromes: prognostic and pathophysiological implications. Clin Chim Acta. 2007;383:103–109
  4. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27:15–26
  5. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004;29:439–493
  6. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007;115:1528–1536
  7. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198–1203
  8. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, et al. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99:224–229
  9. Reilly MP, Pratico D, Delanty N, DiMinno G, Tremoli E, Rader D, et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation. 1998;98:2822–2828
  10. Wang FL, Haubrich DR. A simple, sensitive, and specific assay for free choline in plasma. Anal Biochem. 1975;63:195–201
  11. Ulus IH, Ozyurt G, Korfali E. Decreased serum choline concentrations in humans after surgery, childbirth, and traumatic head injury. Neurochem Res. 1998;23:727–732
  12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–470
  13. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: universal definition of myocardial infarction. Circulation. 2007;116:2634–2653
  14. Adams JE, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, et al. Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation. 1993;88:101–106
  15. Mair J, Wagner I, Puschendorf B, Mair P, Lechleitner P, Dienstl F, et al. Cardiac troponin I to diagnose myocardial injury. Lancet. 1993;341:838–839
  16. Malasky BR, Alpert JS. Diagnosis of myocardial injury by biochemical markers: problems and promises. Cardiol Rev. 2002;10:306–317
  17. Bakshi TK, Choo MK, Edwards CC, Scott AG, Hart HH, Armstrong GP. Causes of elevated troponin I with a normal coronary angiogram. Intern Med J. 2002;32:520–525
  18. Mahajan N, Mehta Y, Rose M, Shani J, Lichstein E. Elevated troponin level is not synonymous with myocardial infarction. Int J Cardiol. 2006;111:442–449
  19. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ II. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990;87:9383–9387
  20. Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation. 2000;102:1007–1013
  21. Pratico D, FitzGerald GA. Generation of 8-epiprostaglandin F2alpha by human monocytes: discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem. 1996;271:8919–8924
  22. Pratico D, Iuliano L, Mauriello A, Spagnoli L, Lawson JA, Rokach J, et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest. 1997;100:2028–2034
  23. Pratico D, Rokach J, Lawson J, FitzGerald GA. F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids. 2004;128:165–171
  24. Brühl A, Hafner G, Loffelholz K. Release of choline in the isolated heart, an indicator of ischemic phospholipid degradation and its protection by ischemic preconditioning: no evidence for a role of phospholipase D. Life Sci. 2004;75:1609–1620
  25. Konstantinova SV, Tell GS, Vollset SE, Nygård O, Bleie Ø, Ueland PM. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr. 2008;138:914–920
  26. Danne O, Möckel M, Lueders C, Mugge C, Zschunke GA, Lufft H, et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol. 2003;91:1060–1067
  27. Yue B, Pattison E, Roberts WL, Rockwood AL, Danne O, Lueders C, et al. Choline in whole blood and plasma: sample preparation and stability. Clin Chem. 2008;54:590–593
  28. Miles RR, Roberts RF, Putnam AR, Roberts WL. Comparison of serum and heparinized plasma samples for measurement of chemistry analytes. Clin Chem. 2004;50:1704–1706
  29. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760–1763
  30. Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in tactics-TIMI 18. Eur Heart J. 2008;29:1096–1102

PII: S0002-9149(09)01015-7

doi: 10.1016/j.amjcard.2009.04.047

American Journal of Cardiology
Volume 104, Issue 5 , Pages 638-643 , 1 September 2009

Article Tools

* Image Usage & Resolution